Hip Osteoarthritis
Conditions
Brief summary
The current management of osteoarthritis is based on non-pharmacological and pharmacological means which include intra-articular injections. The recommendations on the management of hip osteoarthritis stipulate that intra-articular injections of corticosteroid may be considered in patients with an exacerbation not responding to oral treatments. Several recent studies show the effectiveness of intra-articular corticosteroids compared with anesthetics. The intra-articular injection of viscosupplementation alone has never been validated in this indication since controlled studies did not show efficacy over placebo. At present, viscosupplementation is considered an anti-osteoarthritic symptomatic slow-acting and its interest is not yet established in hip osteoarthritis.
Detailed description
Show the superiority of intra-articular injection of viscosupplementation in combination with corticosteroid compared to intra-articular injection of corticosteroid alone in the treatment of hip osteoarthritis.
Interventions
DEVICEExperimental group
patient receive intra articular injection (hip joint) of viscosupplementation in combination with corticosteroid
DEVICEcontrol group
patient receive intra articular injection (hip joint) of corticosteroid alone
Sponsors
CHU de Reims
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patients with hip osteoarthrosis (stage II et III according Kellgren et Lawrence) * walking alone patients * patient consenting to participate to the study * patient enrolled in the national healthcare insurance program * patient older than 18 years
Exclusion criteria
* Patients with hip osteoarthrosis (stage I et IV according Kellgren et Lawrence) * patients with rapidly destructive hip osteoarthritis * patients with inflammatory rheumatism * patients with microcrystalline arthritis * patients with hip osteonecrosis * patients who received corticosteroids during the previous three months * patients who received a intra articular injection of viscosupplementation during the previous six months * patient with haemostatic disorder * patient with consumption of painkillers tier 3
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| improving pain | 3 months | decrease of 20 mm on a visual analog pain scale between the evaluation at day 0 and the evaluation at 3 months |
Countries
France
Outcome results
None listed